Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy a case series study

Medicine (United States)

Volumn 95, Issue 18, 2016, Pages e3595-

  Li, Qiu Yu ^a   Yu, Feng ^a,b   Zhou, Fu De ^a   Zhao, Ming Hui ^a,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY INTERNATIONAL HOSPITAL   (China)

^c Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CHINESE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; YOUNG ADULT; COMBINATION DRUG THERAPY; COMPLICATION; LUPUS NEPHRITIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; SEVERITY OF ILLNESS INDEX; THROMBOTIC MICROANGIOPATHIES;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PLASMAPHERESIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOTIC MICROANGIOPATHIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84969872350     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003595     Document Type: Article

References (52)

1. Furlan M, Robles R, Galbusera M, et al. von Willebrand factorcleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
2. El Karoui K, Hill GS, Karras A, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol. 2012;23:137-148.
3. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.
4. Goldberg RJ, Nakagawa T, Johnson RJ, et al. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis. 2010;56:1168-1174.
5. Kwok SK, Ju JH, Cho CS, et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus. 2009;18:16-21.
6. Letchumanan P, Ng H, Lee L, et al. A Comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology. 2009;48:399-403.
7. Cheung WY. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus-distinct entities or overlapping syndromes? Transfus Apher Sci. 2006;34:263-266.
8. Dold S, Singh R, Sarwar H, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report. Transfus Apher Sci. 2004;31:17-20.
9. Guvenc B, Unsal C, Gurkan E, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol. 2003;22:355-358.
10. Singh R, Saunders B, Scopelitis E. Pancreatitis leaDing to thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a case report and review of literature. Lupus. 2003;12:136-139.
11. Kawasaki Y, Suzuki J, Nozawa R, et al. 12-Year-old girl with hemolytic uremic syndrome as initial symptom of systemic lupus erythematosus and a literature review. Am J Nephrol. 2002;22:576-580.
12. Vasoo S, Thumboo J, Fong K. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus. 2002;11:443-450.
13. Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheu. 1998;28:1-19.
14. Nesher G, Hanna VE, Moore TL, et al. Thrombotic microangiopathic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheu. 1994;24:165-172.
15. Wu L, Yu F, Tan Y, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS System for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83:715-723.
16. KDIGO Clinical Practice Guideline for Glomerulonephritis, Chapter 12. Lupus nephritis. 2012;2:221-232.
17. Merayo-Chalico J, Demichelis-Gómez R, Rajme-López S, et al. Risk factors and clinical profile of thrombotic thrombocytopenic purpura in systemic lupus erythematosus patients. Is this a distinctive clinical entity in the thrombotic microangiopathy spectrum?: A case control study. Thromb Res. 2014;134:1020-1027.
18. Chen M, Chen M, Chen W, et al. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology. 2011;50:768-775.
19. Hu W, Liu Z, Chen H, et al. Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus. 2010;19:1591-1598.
20. Petri M, Orbai A, Alarcón, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-2686.
21. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992;35:630-640.
22. Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32:1107-1118.
23. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kindney Int Suppl. 2012;2:139-274.
24. Yoo S, Lee EY, Huh KH, et al. Role of plasma exchange in ABOincompatible kidney transplantation. Ann Lab Med. 2012;32:283-288.
25. Reverberi R, Reverberi L. Removal kinetics of therapeutic apheresis. Blood Transfus. 2007;5:164-174.
26. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22:270-276.
27. De Silvestro G, Marson P, Russo GE, et al. National survey of apheresis activity in Italy (2000). Transfus Apher Sci. 2004;30:61-71.
28. Norda R, Stegmayr BG. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci. 2003;29:159-166.
29. Zhang YY, Tang Z, Chen DM, et al. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with antiglomerularbasement membrane nephritis. BMC Nephrol. 2014;15:128.
30. Huang J, Han S, Qin D, et al. Renal interstitial arteriosclerotic lesions in lupus nephritis patients: a cohort study from China. PLos One. 2015;10:e0141547.
31. Song D, Wu L, Wang F, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15:1-12.
32. Weening JJ, Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241-250.
33. Austin HA III, Boumpas DT, Vaughan EM, et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544-550.
34. Austin HA III, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689-695.
35. Yu F, Tan Y, Zhao MH. Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome. Nephrol Dial Transplant. 2010;25:145-152.
36. Geerdink L, Westra D, van Wijk JE, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol. 2012;27:1283-1291.
37. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323-335.
38. Xu D, Lv J, Dong Y, et al. Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant. 2012;27(Supple 3):119-125.
39. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med. 2002;137:693-695.
40. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
41. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: populationbased cohort study. BMJ. 2012;344:e977.
42. Siami GA, Siami FS. Cryofiltration Apheresis in the United States. Ther Apher. 1998;2:228-235.
43. Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol. 1996;7:367-386.
44. Samtleben W, Randerson DH, Blumenstein M, et al. Membrane plasma exchange: principles and application techniques. J Clin Apher. 1984;2:163-169.
45. Solomon BA, Castino F, Lysaght MJ, et al. Continuous flow membrane filtration of plasma from whole blood. Trans Am Soc Artif Intern Organs. 1978;24:21-26.
46. Chua JS, Baelde HJ, Zandbergen M. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol. 2015;26:2239-2247.
47. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int. 1991;39:1225-1231.
48. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-736.
49. Cohen D, Koopmans M, Kremer Hovinga ICL, et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum. 2008;58:2460-2469.
50. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2015;65:127-130.
51. Coppo R, Peruzzi L, Amore A, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol. 2015;30:167-172.
52. Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology. 2015;54:2286-2288.